Is Alzheimer’s disease different in people with Down’s? Two recent proteomics studies say yes. In the July 1 Nature Communications, scientists led by Erik Johnson at Emory University School of ...

The role of ApoE has been well-studied outside of the cell, but what happens after it’s let inside? Scientists led by Raimund Dutzler, University of Zurich, have identified Tweety homologue 2 as an ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

In a June 12 conference at UW-Madison, researchers gathered from across the U.S. and abroad to discuss the latest progress on TDP-43 biomarkers. In all, 74 people attended in person, and 727 virtually ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

Other news from AAIC? Long-term lecanemab dosing in open-label extensions now goes out to three years, and continues to support the idea that the antibody slows disease progression. On cognitive ...

A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential ...

Today the U.S. Food and Drug Administration’s advisory committee gave the nod to donanemab, clearing the way for its marketing approval. All 11 members voted that the antibody was effective for people ...